Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
NO-CUT is a one-stage phase II trial seeking to establish whether an oxaliplatin-based
chemotherapy preceding standard neo-adjuvant fluoropyrimidines-based chemo radiotherapy, can
safely spare demolitive surgical intervention in patients with operable rectal cancer,
without increasing the risk of distant relapse. The trial also has a translational component
aimed at establishing whether selected genomic, epigenetic, and transcriptomic markers are
predictive of tumor and patient outcome.